Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology, and Child Health
Reference6 articles.
1. Rodriguez-Morales AJ, Martinez-Pulgarin DF, Muñoz-Urbano M, Gómez-Suta D, Sánchez-Duque JA, Machado-Alba JE. Bibliometric assessment of the global scientific production of nitazoxanide. Cureus. 2017;9:e1204.
2. Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antivir Res. 2014;110:94–103.
3. Aslam S, Musher DM. Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent. Future Microbiol. 2007;2:583–90.
4. Jasenosky LD, Cadena C, Mire CE, et al. The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits ebola virus. iScience. 2019;19:1279–90.
5. Li J, Kuang H, Zhan X. Nitazoxanide in the treatment of intestinal parasitic infections in children: a systematic review and meta-analysis. Indian J Pediatr. 2019. https://doi.org/10.1007/s12098-019-03098-w.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献